Discovery and Development of Anti-inflammatory Agents from Natural Products

 
 
Elsevier (Verlag)
  • 1. Auflage
  • |
  • erschienen am 11. Juli 2019
  • |
  • 332 Seiten
 
E-Book | ePUB mit Adobe-DRM | Systemvoraussetzungen
E-Book | PDF mit Adobe-DRM | Systemvoraussetzungen
978-0-12-816993-3 (ISBN)
 

Discovery and Development of Anti-inflammatory Agents from Natural Products, the latest volume in the Natural Product Drug Discovery series, presents cutting-edge research advances in the field of bioactive natural products and natural drug formulations, with this volume focusing on molecules of natural origin and their synthetic analogues that have the potential to act against the pathogens responsible for inflammatory diseases. All aspects of each are covered, including isolations and structure elucidations, in vitro and in vivo biological activity, synthetic optimization, investigations of pharmacodynamics and kinetics, and the structure-activity relationships of anti-inflammatory natural products.

Written by active researchers and leading experts, this book brings together an overview of current discoveries and trends in this field. It will be a valuable resource for researchers working to discover promising leads for the development of pharmaceuticals in the prevention and treatment of anti-inflammatory diseases.

  • Features contributions from active researchers and leading experts working in medicinal natural products and herbal formulations
  • Includes recent, cutting-edge advances on medicinal natural products, along with preventative therapies for different kinds of inflammation-directed diseases
  • Offers an authoritative source of information on the industrial application of natural products for medicinal purposes
weitere Ausgaben werden ermittelt
  • Front Cover
  • Discovery and Development of Anti-Inflammatory Agents from Natural Products
  • Discovery and Development of Anti-Inflammatory Agents from Natural Products: Natural Product Drug Discovery Series
  • Copyright
  • Dedication
  • Contents
  • Contributors
  • Editor Biography
  • Foreword
  • Preface
  • 1 - Discovery and development of anti-inflammatory agents from natural products: an overview
  • 1. Introduction
  • 2. Overview of the book
  • 2.1 Chapter 2
  • 2.2 Chapter 3
  • 2.3 Chapter 4
  • 2.4 Chapter 5
  • 2.5 Chapter 6
  • 2.6 Chapter 7
  • 2.7 Chapter 8
  • 2.8 Chapter 9
  • 2.9 Chapter 10
  • 3. Concluding remarks
  • 2 - Curcumin: current evidence of its therapeutic potential as a lead candidate for anti-inflammatory drugs-an overview
  • 1. Introduction: general features and ethnopharmacological relevance
  • 2. Isolation, chemical biosynthesis, and characterization of curcumin
  • 3. Pharmacokinetics of curcumin
  • 4. Pharmacodynamics in inflammatory processes
  • 5. Semisynthesis of novel molecules from curcumin
  • 6. Preclinical studies: in vitro and animal research on the anti-inflammatory properties of curcumin and its derivatives
  • 6.1 Edema and global inflammation
  • 6.2 Arthritic diseases
  • 6.3 Gastrointestinal diseases
  • 6.4 Pancreatitis
  • 6.5 Allergy and bronchial asthma
  • 6.6 Cystic fibrosis
  • 6.7 Psoriasis
  • 6.8 Neurodegenerative diseases and cancer
  • 7. Clinical evidence of curcumin's anti-inflammatory benefits
  • 7.1 Arthritic diseases
  • 7.2 Inflammatory diseases of gastrointestinal tract
  • 7.3 Pancreatitis
  • 7.4 Allergy and inflammatory diseases of respiratory tract
  • 7.5 Psoriasis
  • 7.6 Ocular conditions
  • 7.7 Neurodegenerative diseases and cancer
  • 7.8 Other conditions
  • 8. Curcumin as an anti-inflammatory drug: the reality and limitations
  • 9. Concluding remarks
  • List of abbreviations
  • References
  • 3 - Anti-inflammatory efficacy of some potentially bioactive natural products against rheumatoid arthritis
  • 1. Introduction
  • 2. Etiology of disease progression
  • 2.1 Genetic susceptibilities
  • 2.2 Autoimmunity and role of proinflammatory cytokines
  • 3. Current pharmacological treatments of rheumatoid arthritis and their drawbacks
  • 3.1 Nonsteroidal anti-inflammatory drugs
  • 3.2 Glucocorticoids
  • 3.3 Disease-modifying antirheumatic drugs
  • 3.3.1 Methotrexate (Rheumatrex and Trexall)
  • 3.3.2 Hydroxychloroquine (Plaquenil)
  • 3.3.3 Sulfasalazine (Azulfidine)
  • 3.3.4 Leflunomide (Arava)
  • 3.3.5 Intramuscular gold therapy
  • 3.4 Biological agents
  • 3.4.1 Tumor necrosis factor inhibitors
  • 3.4.2 T-cell costimulatory blocking agents
  • 3.4.3 B cell-depleting agents
  • 3.4.4 Interleukin-6 inhibitors
  • 3.4.5 Interleukin-1 receptor antagonists
  • 4. Protective role of naturally occurring anti-inflammatory compounds
  • 4.1 Phenolic compounds
  • 4.1.1 Phenolic acids
  • 4.1.1.1 Benzoic acid derivatives
  • 4.1.1.2 Cinnamic acid derivatives
  • 4.1.2 Flavonoids
  • 4.1.2.1 Flavones
  • 4.1.2.2 Flavonols
  • 4.1.2.3 Flavanones
  • 4.1.2.4 Isoflavonoid
  • 4.1.2.5 Anthocyanins
  • 4.1.3 Stilbenoid
  • 4.1.4 Diarylheptanoids and arylalkanones
  • 4.2 Terpenoid compounds
  • 4.3 Alkaloid compounds
  • 5. Concluding remarks: challenges and future prospects
  • List of abbreviations
  • References
  • 4 - Natural anti-inflammatory agents for the management of osteoarthritis
  • 1. Introduction
  • 2. Current treatments and their disadvantages
  • 2.1 Nonpharmacological therapy
  • 2.2 Pharmacological therapy
  • 3. Significance of natural products in the management of osteoarthritis
  • 4. Natural anti-inflammatory agents for management of osteoarthritis
  • 4.1 Boswellia serrata
  • 4.1.1 Anti-inflammatory mechanism
  • 4.2 Harpagophytum procumbens
  • 4.2.1 Anti-inflammatory mechanism
  • 4.3 Glycosaminoglycans
  • 4.3.1 Glucosamine sulfate
  • 4.3.2 Hyaluronic acid
  • 4.3.3 Chondroitin sulfate
  • 4.4 Flavocoxid
  • 4.4.1 Anti-inflammatory mechanism
  • 4.5 Resveratrol
  • 4.6 Other agents
  • 5. Concluding remarks
  • List of abbreviations
  • Acknowledgements
  • References
  • 5 - Portrait of the synthesis of some potent anti-inflammatory natural products
  • 1. Introduction
  • 2. Total synthetic approaches for some anti-inflammatory natural products
  • 2.1 Parthenolide
  • 2.1.1 Introduction to parthenolide
  • 2.1.2 Total synthesis of parthenolide
  • 2.2 C-7 epimer of parthenolide
  • 2.3 1,8-Cineole and 1,4-cineole
  • 2.3.1 Introduction to 1,8-cineole and 1,4-cineole
  • 2.3.2 Total synthesis of 1,8-cineole and 1,4-cineole via terpene or isoprene
  • 2.3.3 Total synthesis of 1,8-cineole and 1,4-cineole by a-terpineol
  • 2.3.4 Formation of 1,8-ceniole through complex formation
  • 2.4 Botryosphaeridione
  • 2.4.1 Introduction to botryosphaeridione
  • 2.4.2 Total synthesis of botryosphaeridione
  • 2.4.3 Synthesis of potent analog of botryosphaeridione
  • 2.5 Cucurbitaceae
  • 2.5.1 Introduction to cucurbitaceae
  • 2.5.2 Total synthesis of cucurbitacins
  • 2.5.3 Synthesis of potent analogs of cucurbitacins
  • 2.6 Astaxanthin
  • 2.6.1 Introduction to astaxanthin
  • 2.6.2 Methodologies for total synthesis of astaxanthin
  • 2.6.3 Stereoselective approach for total synthesis of astaxanthin
  • 2.7 Pseudopterosins
  • 2.7.1 Introduction to pseudopterosins
  • 2.7.2 Total synthesis of pseudopterosin a from chiral pool S-(-)-limonene
  • 2.7.3 Potent analogs of pseudopterosin A
  • 2.8 Fuscosides
  • 2.8.1 Introduction to fuscosides
  • 2.8.2 Total synthetic methodology for fuscol
  • 2.8.3 Synthesis of library of potent analogues of fuscol
  • 2.9 Flavonoids
  • 2.9.1 Introduction to flavonoids
  • 2.9.2 Total synthesis of natural flavonoids
  • 2.9.3 Total synthesis of potent analogues of flavonoid
  • 2.10 Manoalide
  • 2.10.1 Introduction to manoalide
  • 2.10.2 Total synthetic studies on manoalide
  • 2.10.3 Synthesis of potent analogs of manoalide
  • 2.11 Saponins
  • 2.11.1 Introduction to saponins
  • 2.11.2 Saponin total synthesis
  • 2.11.3 Potent analogues of oleanolic acid and ursolic acid
  • 3. Concluding remarks
  • List of Abbreviations
  • References
  • Further reading
  • 6 - Recent developments in the anti-inflammatory potential of sesquiterpene lactones and their semisynthetic analogs
  • 1. Introduction
  • 2. Anti-inflammatory activity of sesquiterpene lactones
  • 2.1 Costunolide
  • 2.2 Parthenolide
  • 2.3 Helenalin
  • 2.4 Miscellaneous guaianolides
  • 2.5 Miscellaneous germacranolides
  • 2.6 Eudesmanes
  • 2.7 Budlein
  • 2.8 Frullanolides
  • 2.9 Miscellaneous sesquiterpene lactones
  • 3. Structure-activity relationships (SAR) of sesquiterpenes lactones
  • 4. Concluding remarks
  • List of abbreviations
  • Acknowledgments
  • References
  • 7 - Hesperetin and naringenin: protective effects against metabolic syndrome-associated inflammation
  • 1. Introduction
  • 1.1 Obesity and metabolic syndrome
  • 1.2 Inflammatory pathways in metabolic syndrome
  • 1.3 Drugs effects in metabolic syndrome-associated inflammation
  • 2. Hesperetin and naringenin: effects on metabolic syndrome-associated inflammation
  • 2.1 Hesperetin
  • 2.2 Naringenin
  • 3. Flavanone chemistry, structure-activity relation, and natural sources
  • 3.1 Flavanone chemistry
  • 3.2 Structure-activity relations
  • 3.3 Natural sources of naringenin and hesperetin
  • 4. Fermentative and enzymatic biotransformation for hesperetin and naringenin
  • 4.1 Enzymatic biotransformation
  • 4.2 Microbial biotransformation
  • 5. Flavanone purification and identification
  • 5.1 Flavanone extraction
  • 5.2 Flavanone purification
  • 5.3 Flavanone identification
  • 6. Concluding remarks
  • List of abbreviations
  • References
  • 8 - Therapeutic implications of anti-inflammatory natural products in Alzheimer's disease
  • 1. Introduction
  • 2. Neuroinflammation in Alzheimer's disease
  • 3. Implementation of anti-inflammatory natural products in Alzheimer's disease
  • 3.1 Curcumin
  • 3.2 Apigenin
  • 3.3 Resveratrol
  • 3.4 Cannabinoids
  • 3.5 Lipoic acid
  • 3.6 Omega-3 fatty acids
  • 3.7 Epigallocatechin-3-gallate
  • 3.8 Diosgenin
  • 3.9 Prosapogenin III
  • 3.10 Quercetin
  • 3.11 Rosmarinic acid
  • 3.12 6-Shogaol
  • 3.13 Huperzine A
  • 4. Concluding remarks
  • List of Abbreviations
  • References
  • 9 - Anti-inflammatory effects of probiotics
  • 1. Introduction
  • 2. Historical aspects
  • 3. Probiotic strains
  • 3.1 Genus Lactobacillus
  • 3.2 Genus Bifidobacterium
  • 3.3 Other microorganisms
  • 3.4 Safety
  • 4. Mechanisms of action
  • 4.1 Cell-to-cell interaction
  • 4.2 Antimicrobial activity
  • 4.3 Immunomodulatory activity
  • 5. Therapeutic use of probiotics
  • 5.1 Gastrointestinal diseases
  • 5.2 Respiratory diseases
  • 5.3 Allergies and dermatitis
  • 5.4 Cancer
  • 6. Concluding remarks
  • List of Abbreviations
  • References
  • Further reading
  • 10 - 6-Gingerol: a therapeutically potent lead candidate in anti-inflammatory drug discovery
  • 1. Introduction
  • 2. Biosynthesis of 6-gingerol
  • 3. Anti-inflammatory potential of 6-gingerol
  • 4. Pharmacokinetics of 6-gingerol
  • 5. Safety of 6-gingerol
  • 6. Concluding remarks
  • References
  • Index
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z
  • Back Cover

Dateiformat: ePUB
Kopierschutz: Adobe-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat ePUB ist sehr gut für Romane und Sachbücher geeignet - also für "fließenden" Text ohne komplexes Layout. Bei E-Readern oder Smartphones passt sich der Zeilen- und Seitenumbruch automatisch den kleinen Displays an. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Bitte beachten Sie bei der Verwendung der Lese-Software Adobe Digital Editions: wir empfehlen Ihnen unbedingt nach Installation der Lese-Software diese mit Ihrer persönlichen Adobe-ID zu autorisieren!

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Dateiformat: PDF
Kopierschutz: Adobe-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat PDF zeigt auf jeder Hardware eine Buchseite stets identisch an. Daher ist eine PDF auch für ein komplexes Layout geeignet, wie es bei Lehr- und Fachbüchern verwendet wird (Bilder, Tabellen, Spalten, Fußnoten). Bei kleinen Displays von E-Readern oder Smartphones sind PDF leider eher nervig, weil zu viel Scrollen notwendig ist. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Bitte beachten Sie bei der Verwendung der Lese-Software Adobe Digital Editions: wir empfehlen Ihnen unbedingt nach Installation der Lese-Software diese mit Ihrer persönlichen Adobe-ID zu autorisieren!

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Download (sofort verfügbar)

232,05 €
inkl. 5% MwSt.
Download / Einzel-Lizenz
ePUB mit Adobe-DRM
siehe Systemvoraussetzungen
PDF mit Adobe-DRM
siehe Systemvoraussetzungen
Hinweis: Die Auswahl des von Ihnen gewünschten Dateiformats und des Kopierschutzes erfolgt erst im System des E-Book Anbieters
E-Book bestellen